Gamida Cell to Host Virtual Thought Leader Fireside Chat on December 4, 2023 Nov 27, 2023 08:11PM
Gamida Cell Reports Second Quarter and First Half 2023 Financial Results and Provides Company Update Aug 14, 2023 07:00AM
Gamida Cell to Report Second Quarter 2023 Financial Results Aug 1, 2023 08:00AM
Data Published in Transplantation and Cellular Therapy Suggest Antiviral Protection After Transplantation with Gamida Cell’s Omisirge® (omidubicel-onlv) Jul 11, 2023 08:00AM
STAND UP TO CANCER NAMES JULIAN ADAMS, Ph.D., CHIEF SCIENCE OFFICER Jul 10, 2023 02:00PM
View Older Stories

Jun 14, 2023 04:30PM Gamida Cell To Host Investor Day
May 31, 2023 04:30PM Gamida Cell to Present Corporate Highlights at the Jefferies Healthcare Conference
May 31, 2023 07:00AM Data To Be Presented on Gamida Cell Natural Killer (NK) Cell Therapy Candidate GDA-201 at the International Society for Cell & Gene Therapy 2023 Annual Meeting
May 22, 2023 08:00AM Gamida Cell Appoints Terry Coelho as CFO
May 15, 2023 04:05PM Gamida Cell Reports First Quarter 2023 Financial Results and Provides Company Update
Apr 17, 2023 04:16PM Gamida Cell Ltd. (GMDA) Announces FDA Approval of Omisirge
Apr 17, 2023 04:16PM Gamida Cell’s Allogeneic Cell Therapy Omisirge® (omidubicel-onlv) Receives FDA Approval
Mar 27, 2023 07:00AM Gamida Cell Reports Full Year 2022 Financial Results and Provides Company Update
Mar 20, 2023 04:30PM Gamida Cell (GMDA) Announces Changes to Board of Directors
Mar 20, 2023 04:30PM Gamida Cell Announces Changes to Board of Directors
Mar 20, 2023 08:00AM Gamida Cell Announces the Date of Its Fourth Quarter and Full Year 2022 Financial Results and Webcast
Mar 7, 2023 08:00AM Gamida Cell to Present Corporate Highlights at the Oppenheimer 33rd Annual Healthcare Conference
Feb 18, 2023 12:30PM Data Presented on Gamida Cell’s Omidubicel, GDA-201 at the 2023 Tandem Meetings of ASTCT and CIBMTR
Dec 12, 2022 07:00AM Gamida Cell Announces Closing of $25 Million Financing With Highbridge
Nov 23, 2022 08:00AM Gamida Cell to Present Corporate Highlights at Multiple Upcoming Investor Conferences
Nov 21, 2022 04:53PM Gamida Cell Ltd. (GMDA) Provides Update on Omidubicel
Nov 21, 2022 04:52PM Gamida Cell Provides Regulatory Update on Omidubicel
Nov 14, 2022 07:00AM Gamida Cell Reports Third Quarter 2022 Financial Results and Provides Company Update
Nov 10, 2022 08:00AM Gamida Cell to Present Corporate Highlights at the Jefferies London Healthcare Conference
Nov 7, 2022 08:14AM Gamida Cell Ltd. (GMDA) Announces GDA-501, NAM enabled NK Cell Therapy, Demonstrates Promising Antitumor Activity Against HER2+ Cancers
Nov 7, 2022 08:00AM Gamida Cell Announces the Date of Its Third Quarter 2022 Financial Results and Webcast
Nov 7, 2022 08:00AM GDA-501, NAM enabled NK Cell Therapy, Demonstrates Promising Antitumor Activity Against HER2+ Cancers
Nov 3, 2022 09:07AM Gamida Cell Announces Omidubicel Data To Be Presented as an Oral Presentation at 64th ASH Annual Meeting
Oct 10, 2022 07:00AM  Gamida Cell to Present Corporate Highlights at 2022 Cell & Gene Meeting on the Mesa
Sep 29, 2022 07:04AM Gamida Cell (GMDA) Announces Long-Term Data from Omidubicel Phase 3 Trial Demonstrates OS and Sustainable Durable Outcomes for Patients with Blood Cancers
Sep 29, 2022 07:00AM Long-Term Data from Omidubicel Phase 3 Trial Demonstrates Overall Survival and Sustainable Durable Outcomes for Patients with Blood Cancers at the Society of Hematologic Oncology Meeting
Sep 28, 2022 12:08AM Gamida Cell Announces Entry into Commitment Letter with Highbridge for $25 Million Financing
Sep 19, 2022 07:03AM Gamida Cell (GMDA) Appoints Abigail L. Jenkins as President and Chief Executive Officer
Sep 19, 2022 07:00AM Gamida Cell Appoints Abigail L. Jenkins as President and Chief Executive Officer, Bringing Broad Leadership Experience in Commercializing Innovative Therapies
Sep 12, 2022 08:00AM Gamida Cell Presents Data Demonstrating the Impact of Transplantation with Omidubicel for Patients with Hematologic Malignancies at 2022 Cord Blood Connect Meeting
Aug 15, 2022 07:00AM Gamida Cell Reports Second Quarter 2022 Financial Results and Provides Company Update
Aug 10, 2022 07:00AM Gamida Cell Announces Dosing of First Patient in Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201
Aug 8, 2022 08:00AM Gamida Cell Announces the Date of Its Second Quarter 2022 Financial Results and Webcast
Aug 1, 2022 07:03AM Gamida Cell (GMDA) Announces FDA Acceptance of Biologics License Application for Omidubicel with Priority Review
Aug 1, 2022 07:00AM Gamida Cell Announces FDA Acceptance of Biologics License Application for Omidubicel with Priority Review
Jun 13, 2022 07:00AM Gamida Cell to Present Corporate Highlights at the JMP Securities Life Sciences Conference
Jun 10, 2022 07:00AM Gamida Cell Appoints Ivan M. Borrello, M.D., Expert in Immuno-Oncology, Cell Therapies, and Bone Marrow Transplant to Board of Directors
Jun 2, 2022 07:03AM Gamida Cell Ltd. (GMDA) Completes Rolling Omidubicel BLA Submission to FDA
Jun 2, 2022 07:00AM Gamida Cell Completes Rolling Biologics License Application Submission to the FDA for Omidubicel
Jun 1, 2022 04:30PM Gamida Cell to Present Corporate Highlights at the Jefferies Healthcare Conference
Jun 1, 2022 07:00AM Gamida Cell Announces Opening to Enrollment of Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201
May 17, 2022 04:30PM Gamida Cell to Present Corporate Highlights at the H.C. Wainwright Global Life Sciences Conference
May 10, 2022 07:00AM Gamida Cell Reports First Quarter 2022 Financial Results and Provides Company Update
May 5, 2022 07:08AM Gamida Cell Ltd. (GMDA) Presents New Data from NAM-Enabled Genetically Modified Natural Killer (NK) Pipeline
May 5, 2022 07:00AM Gamida Cell Presents New Data from NAM-Enabled Genetically Modified Natural Killer (NK) Pipeline at International Society for Cell & Gene Therapy 2022
May 3, 2022 08:00AM Gamida Cell Announces the Date of Its First Quarter 2022 Financial Results and Webcast
Apr 27, 2022 07:00AM Gamida Cell Ltd. (GMDA) Reports Updated One-Year Post-Transplant Follow Up Data from Phase 3 Study of Omidubicel
Apr 27, 2022 07:00AM Gamida Cell Presents Updated One-Year Post-Transplant Follow Up Data from Phase 3 Study of Omidubicel at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings
Apr 26, 2022 07:00AM Gamida Cell Ltd. (GMDA) Announces FDA Clearance of IND and Removal of Clinical Hold for NK Cell Therapy Candidate GDA-201
Apr 26, 2022 07:00AM Gamida Cell Announces FDA Clearance of IND and Removal of Clinical Hold for NK Cell Therapy Candidate GDA-201
View Older Stories